

# **Akzeptanzorientierte Drogenarbeit/ Acceptance-Oriented Drug Work**

ISSN 1861-0110

INDRO e.V.

---

Kommentar / Commentary

**Opioid substitution treatment (OST) for prisoners: Practices, problems and perspectives**

**[Substitutionsbehandlung mit Opioiden für Strafgefangene: Praxis, Probleme und Zukunftsperspektiven]**

HEINO STÖVER (PROF, DR. PHIL./PROF, PHD)

© INDRO e.V., Bremer Platz 18-20, D-48155 Münster, Germany. Jegliche Vervielfältigung, Verbreitung und Zitation von Textpassagen ausdrücklich gestattet unter Angabe der Originalquelle / verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL: **Akzeptanzorientierte Drogenarbeit/Acceptance-Oriented Drug Work 2010;7:20-32**, URL: [www.indro-online.de/Stoever2010.pdf](http://www.indro-online.de/Stoever2010.pdf)

## **Abstract**

Drug use is prevalent throughout prison populations, and, despite advances in drug treatment programmes for inmates, access to and the quality of these programmes remain substantially poorer than those available for non-incarcerated drug users. Because prisoners may be at greater risk for some of the harms associated with drug use, they deserve therapeutic modalities and attitudes that are at least equal to those available for drug users outside prison. This paper discusses drug use by inmates and its associated harms. In addition, this paper provides a survey of studies conducted in prisons of opioid substitution therapy (OST), a clinically effective and cost-effective drug treatment strategy. The findings from this overview indicate why treatment efforts for drug users in prison are often poorer than those available for drug users in the non-prison community and demonstrate how the implementation of OST programmes benefits not only prisoners but also prison staff, the institution in general and the community at large. This article is focussing on the reasons for the limited offer of OST, the problems of provision of addiction medicine, and discusses solutions. Finally, the paper outlines strategies that have been found effective for implementing OST in prisons and offers suggestions for applying these strategies more broadly.

## **Introduction: Drug use by prisoners**

Drug use remains endemic among incarcerated populations [1,2]. In Europe, the prevalence of drug dependence among prisoners varies from country to country; a systematic review of the literature found the prevalence to range from 10% to 48% for male prisoners and 30% to 60% for female prisoners at the point of incarceration [3]. In the United States, the number of people incarcerated annually for drug-related offenses in

the past 20 years has grown from 40,000 to 450,000, leading to prison populations with high rates of drug use [4]. Imprisonment of drug users for crimes they commit—often to support their addiction—contributes to prisoners' high prevalence of drug dependence [5]. A lifetime history of incarceration is common among intravenous drug users (IDUs); 56% to 90% of IDUs have been imprisoned previously [6]. Drug-using prisoners may be continuing a habit acquired before incarceration or may acquire the habit in prison [7,8]. In Europe, 16% to 60% of prisoners who injected outside prison continued to inject while incarcerated [5], whereas 7% to 24% of prisoners who injected said they started in prison [5]. In another study, one-fifth of prisoners injected drugs for the first time in prison [9].

Imprisonment also favours high-risk behaviour regarding drugs because of concentrated at-risk populations and risk-conducive conditions such as overcrowding and violence. The consequences of drug use in prison include drug-related deaths, suicide attempts and self-harm. Drug use tends to be more dangerous inside than outside prisons because of the scarcity of drugs and sterile injecting equipment [5,10,11]. In a study of 492 IDUs, 70.5% reported sharing needles while in prison compared with 45.7% who shared needles in the month before imprisonment ( $P < 0.0001$ ) [9]. Of particular concern is that sharing injecting equipment inside prisons is a primary risk factor for human immunodeficiency virus (HIV) transmission [12]. Additionally, hepatitis C virus (HCV) infection through shared injecting equipment in prison has been reported in studies undertaken in Australia [13,14] and Germany [15]. Drug use in prison is also associated with the risk for involvement in violence. Inmates who incur disciplinary action related to possession or use of a controlled substance or contraband were 4.9 times more likely to display violent or disruptive behaviour than those who did not incur such disciplinary action [16]. Prisoners using drugs are also at risk for engaging in further illicit activity [17]. If discovered using illegal drugs, inmates risk prolonged incarceration for breaking security rules and eliciting hostility among prison staff [2,12].

Unless a prisoner receives adequate treatment, drug addiction and dependence and their attendant dangers persist after the prisoner's release into the community and are associated with a high rate of overdose and other harms. Overall, the determining factor in drug-related deaths soon after release appears to be altered tolerance to opioids [18]. In the week after release, prisoners are approximately 40 times more likely to die than are members of the general population; in this immediate post-release period, more than 90% of deaths are drug related [18]. Among women, the odds of a drug-related death in the first week after release were >10 times greater than at 52 weeks (overall risk [OR] = 10.6; 95% confidence interval [CI] = 4.8–22.0); among men, the odds were ~8 times greater (OR = 8.3; 95% CI = 5.0–13.3) [19]. Very high rates of drug-related mortality persist at least through the first 2 weeks after release from prison [20]. Among the costs to society for an inmate's failure to fully reform while in prison is increased risk for recidivism. Within 12 months of release from prison, 58% of heroin users who did not receive opioid substitution therapy (OST) were re-incarcerated compared with 41% of those who did receive OST [21]. Furthermore patients in intramural OST benefit substantially from the treatment: Larney [54 found out that compared to inmates in control conditions, for treated inmates the risk of injecting drug use was reduced by 55–75% and risk of needle and syringe sharing was reduced by 47–73%. This paper provides a non-systematic overview of the literature comparing the quality of drug treatment for inmates with their non-incarcerated counterparts. Guidance regarding the implementation of drug treatment programmes was collected from the literature and included herein. All searches were conducted using Web-based search engines (e.g. PubMed, EMBASE) or abstract archiving system (e.g. SciFinder) combining terms related to incarceration (eg, prison, prisoner) with terms related to drug misuse and treatment (eg, heroin, OST); the end date for searches was December 2009.

### **Current state of drug treatment health care efforts for inmates**

Many data attest to the low quality or non-existence of drug treatment health care efforts for prisoners com-

pared with efforts made for non-prisoner drug users. For example, in early 2007, 24 of 25 European Union member states had needle exchange programmes in the community, but only three had such programmes in prisons, and only Spain covered all prisons [7], although the process of implementation has not been fully finalised. An international survey reported in 2009 that at least 37 countries offered OST in community settings but not in prison settings [22]. European countries not offering OST in prison include Bulgaria, Cyprus, Estonia, Greece, Latvia, Lithuania, Slovakia and Sweden [22]. OST was considered any treatment for opioid dependence using a medicinal opioid such as methadone, buprenorphine, or buprenorphine/naloxone [22]; this differs from methadone maintenance treatment (MMT), in which methadone is the only agent used for substitution therapy.

Universally, the percentage of drug users offered OST varied considerably from prison to prison (from 2% to 16.2%) but utilisation of these programmes was uniformly low (e.g. 7.8% of drug addicts in French prisons received OST) [23]. In most European countries that offered OST in prison, access to and varieties of available OST programmes were heterogeneous and inconsistent [5,24]. For example, although OST is nominally available in German prisons, implementation is the responsibility of each of the 16 federal states and often varies from prison to prison within states and sometimes even from doctor to doctor within one prison [25]. Whereas the substitution coverage rate (demand and offer) in the community is between 40-50%, the coverage rate in prisons is around 3% [50]. A recent study found out that undergoing OST at the time of their imprisonment, 70% had to stop treatment when they entered prison [55]. In France, many physicians have been reluctant to initiate OST in prison or even to renew existing buprenorphine or methadone prescriptions for prisoners [26]. If substitution treatment is provided, it is often limited to drug detoxification [5,17]. Furthermore, most efforts to scale up OST in the community have not been carried through to the prison setting [24,27,28; see graphic 1].


### **Why is drug treatment for prisoners not yet comparable to that available for non-incarcerated drug users?**

Several factors affect the extent to which prisons provide OST, including the varied health policies of prisons and the difficulties in employing adequate numbers and quality of prison staff [26]. Some prisoners are prevented from entering an OST programme because of excessively restrictive criteria [22]. For example, in some countries OST is limited to inmates who are serving sentences of a particular length, were in treatment before imprisonment or can confirm that they are enrolled in a post-release treatment programme [22]. In Croatia, OST is restricted to persons aged 25 and older who used illegal drugs for  $\geq 10$  years and heroin for  $\geq 5$  years [29]. Other limitations related to OST in prisons include a deficiency of psychological and social support for drug-using prisoners [5] and lack of or limited access to certain OST programmes, such as buprenorphine-based regimens, that may be more suitable for use in prison [27,30].

Several theoretical and functional reasons have resulted in drug treatment for prisoners not having parity with drugs users in the community. In particular, some societal misconceptions pervade the medical management of drug dependence. There exists a poor understanding of opioid dependence as a chronic and recurring disease; some clinicians may feel that a hedonistic practice indicates a weakness of character [5,24]. Another widespread but mistaken belief involves the benefits of abstinence for drug users, which leads to the omission of maintenance therapy after detoxification, which in turn leads to reversion to opioid use [31]. In Her Majesty's Prison at Leeds, 43% of prisoners with an illicit opioid habit continued to acquire and use opioids even through the first days of imprisonment and completion of a detoxification regimen [32]. Apart from negative attitudes, misconceptions and misunderstandings, there are also socioeconomic reasons drug-using prisoners, particularly IDUs, do not receive appropriate therapy for their drug problem: they are frequently poor and deprived and, therefore, marginalised [33] and not considered worthy of treatment. These beliefs delay the implementation of OST, as does the common perception that prisons should be "drug-free zones" [5]. Prison

authorities may also be concerned that OST undermines their efforts to reduce the drug supply in their institutions (ie, a black market for drugs) [5,33] and that providing needles is, in effect, placing “weapons” in inmates’ hands [26].

**Graphic 1:** Provision of substitution/maintenance treatment (OST) in the community and availability of OST Programmes in the prison system in 2007 in the EU (excluding Sweden). Source: EMCDDA 2009: Structured questionnaire on ‘treatment programmes’ (SQ27/P1), submitted by National Focal Points (NFPs) in 2008



Notes:

Data were not available for Sweden.

#### Rating Scales

##### PRISON

Full: substitution/maintenance treatment exists in nearly all prisons

Extensive: exists in a majority of prisons but not in nearly all of them

Limited: exists in more than a few prisons but not in a majority of them

##### COMMUNITY (provision in relation to the needs of target group POU):

Full: nearly all POU

Extensive: a majority but not nearly all POU would obtain OST

Limited: more than a few but not a majority of POU would obtain OST

Rare: just a few POU would obtain OST

## **Rationales for drug dependence treatment in prisons**

### ***Benefits for the prisoner***

There are many reasons drug-using prisoners should be afforded the same quality of health care regarding drug maintenance treatment—including OST—as is available to non-prisoners [12,34,35]. Primarily, it is appropriate to treat prisoners' drug use so that they will not leave prison in worse health than when they entered [33]. OST is recognised as one of the most effective treatment options for opioid dependence [34]. It can decrease the high cost of opioid dependence to users, their families and society at large by reducing heroin use, associated deaths, HIV-risk behaviours and criminal activity. Substitution maintenance therapy is established as a critical component of community-based approaches in the management of opioid dependence.

Many studies have demonstrated the successful application of OST in prison populations with regard to prisoner-centred and non-prisoner-centred outcomes. Positive prisoner-centred outcomes associated with OST include reduced rates of drug abuse and infectious diseases. Prisoners receiving MMT have shown less drug injecting [11,36,37] and less risk-taking behaviour (e.g. sharing of syringes) [11,38]. In one study, only 1 of 18 (5.6%) prisoners receiving MMT reported heroin use in the past 30 days compared with 15 of 40 (37.5%) prisoners not receiving MMT ( $P < 0.05$ ) [36]. After 4 months in prison, illicit use of morphine was 27% for MMT-treated prisoners and 42% for controls ( $P = 0.05$ ) [39]. The use of buprenorphine maintenance therapy in prisons has been based chiefly on results obtained outside prisons [23,25]; however, there is growing experience with buprenorphine in prisons [29]. A group of prisoners receiving buprenorphine reported for their designated post-release treatment programme significantly more often than did a comparison group receiving methadone (48% vs. 14%, respectively;  $P < 0.001$ ) [40]. A 2-year study in Puerto Rico is under way to examine the feasibility of initiating prisoners with histories of heroin addiction on buprenorphine/naloxone before their release to determine the effectiveness of such treatment with regard to post-release treatment entry, reduction in heroin use and reduction in criminal activity at 1 month after release [41].

OST in prison has also been associated with reduced rates of infectious disease. Adequate OST has been associated with reduced risk for HCV infection [39], whereas inadequate MMT—periods of  $<5$  months in one study, for example—was found to be significantly associated with increased risk for HCV seroconversion ( $P = 0.01$ ) [42]. Prisoners receiving MMT with a daily dose  $>60$  mg during their whole prison sentence were found to be least likely to inject heroin, share needles and engage in HIV risk-taking behaviour while in prison [38]. In another study, needle-sharing and drug-injecting behaviour decreased significantly among prisoners receiving MMT for  $>6$  months [43]. Additionally, in Spain, there was a significantly reduced sharing of needles by IDU prisoners in an OST programme (Marco A, 1995, personal communication). OST has also been associated with a reduced risk for prisoner death. In one study, no deaths were recorded while prisoners were enrolled in MMT, whereas 17 prisoners died while not enrolled in MMT, representing an untreated mortality rate of 2.0 per 100 person-years (95% CI, 1.2–3.2) [42]. Finally, prisoners receiving MMT have shown a decrease in serious violent drug charges over time, whereas those not receiving MMT showed an increase [21].

Other positive prisoner-centred outcomes related to OST in prison can be observed after the term of incarceration is completed. Reduced drug use after release was reported among prisoners engaged in an MMT plan [35]. The mean number of days in community-based drug abuse treatment 1 year post-release—as a function of in-prison treatment for drug abuse—was 23.1 days' counselling only in prison; 91.3 days' counselling plus passive transfer to treatment upon release; and 166.0 days' counselling plus methadone treatment in prison and continued post-release (each pairwise comparison,  $P < 0.01$ ). Participants in the counselling-plus-methadone group were significantly less likely than those in the other groups to have opioid-positive or cocaine-positive urine drug test results [44]. OST also lessens the likelihood of released prisoners committing crimes [35]. The reported number of days of criminal activity in the past 365 days after release was 106.7

(standard deviation [SD] = 128.7) with counselling only; 65.2 (SD = 96.2) counselling plus transfer to methadone; and 81.8 (SD = 109.5) days counselling plus methadone [44]. Reduced recidivism was reported among prisoners engaged in some type of OST [35]. Prisoners on a 12-month MMT while incarcerated had a lower level of re-incarceration than heroin-using prisoners with no treatment [21]. Reduced rates of re-incarceration during a 3½-year period following a first incarceration were related to maintenance OST in prison [46]. A Correctional Service of Canada study found that, after 1 year, 41% of addicted inmates receiving MMT were re-admitted to prison compared with 58% of addicted inmates who were not receiving the treatment [46]. Compared with periods of no MMT in prison, the risk for re-incarceration was reduced by 70% during MMT periods  $\geq 8$  months ( $P < 0.001$ ) [42].

### ***Benefits for the prison staff and community***

A major rationale for the use of OST in prison is the cost-effectiveness of such a strategy. For example, prison methadone is no more costly than community methadone and provides the benefit of reduced heroin use in prisons with the associated reductions in morbidity and mortality [47]. The cost of an institutional OST programme may be offset by the cost savings accruing from offenders successfully remaining in the community longer than equivalent offenders not receiving OST [21,47]. Expanded access to MMT has an incremental cost-effectiveness ratio of  $< \$11,000$  per quality-adjusted life-year, which is more cost-effective than many widely used medical therapies [48]. Implementing OST in prisons is also associated with improvement in inmate manageability and prison safety; total institutional charges for prisoners enrolled in MMT are lower than for prisoners not enrolled in MMT [21]. Reduced drug use and reduced recidivism were reported among prisoners engaged in methadone treatment [35].

### **Strategies for implementing appropriate maintenance therapy in prisons**

the more successful strategies for implementing appropriate maintenance therapy in prisons are those used in Spain and the United Kingdom. The mechanics of these programmes may be applicable in other countries that want to implement appropriate maintenance programmes in prisons.

#### ***The Spain model***

For more than 10 years, all prisons in Spain have had a legal duty to implement MMT programmes involving syringe exchanges. Incoming prisoners are given a full medical examination, and those who are drug users are offered a treatment programme in which medications are given daily. The laboratory-produced methadone is pre-packaged with the dose for each prisoner in the programme. Prisoners must present identification at the point of medication dispensing and are watched to ensure that the complete dose is taken [49].

#### ***The United Kingdom model***

In the United Kingdom, the prison programme (Integrated Drug Treatment System [IDTS]) is funded to provide OST in every adult prison, within an integrated clinical and psychosocial treatment approach, uniting prisons' psychosocial drug treatment services (counselling, assessment, referral, advice and through-care services) and clinical substance misuse management (incorporating the option of MMT or detoxification) services [51,52, 53]. The design of the programme took into account the vulnerability of drug-using prisoners to suicide and self-harm in prison and to death upon release from prison because of accidental opioid overdose, prison regimen services that correspond to national and international good practice and the need to provide clinical interventions that harmonise with practice in the community and other criminal justice settings.

The United Kingdom programme organised five "work streams" to develop national policies and strategies that would (1) facilitate the integration of the two halves of IDTS; (2) develop a guidance document indicating how IDTS would work with community and criminal justice partners; (3) design and commission a large re-

search study of IDTS; (4) develop a workforce strategy, setting out the knowledge and skills requirements for staff involved in IDTS; and (5) produce a performance management framework, setting out how indicators of performance would be collated.

Training was planned to ensure that staff responsible for the well-being or treatment of IDTS service users had the requisite knowledge and skills for the role. Funding for the United Kingdom programme included a sufficient amount for the purchase and installation in prisons of computer-controlled methadone-dispensing devices. IDTS partners received guidance on staff recruitment, with materials for a national advertising campaign. The creation of shared locations in prisons for IDTS team members and the provision of adequate space for IDTS facilities, including harm minimisation groups and treatment rooms, were actively encouraged. From 2008 to 2009, more than 19,000 MMT treatments were administered in United Kingdom prisons; this number will continue to increase until the full implementation of the IDTS programme occurs in 2010 to 2011.

### **Guidance on overcoming barriers to the implementation of substitution programmes in prisons**

#### ***Overcoming barriers from the prisoner***

Prisoner resistance to participation in a maintenance programme is often based on a lack of desire to be treated. Of 140 eligible men approached to take part in a study of opioid detoxification, 36% declined to be recruited [32]. A similar lack of desire to be treated may be seen with regard to OST. Some prisoners may resist participating in a programme because they do not want their partners or relatives to know they have been using drugs. Some may resist treatment with methadone because they consider methadone a street drug.

Prisoners' refusal to participate in a maintenance programme is best addressed by improving prisoner education. Prisoners may be convinced to participate in a substitution maintenance programme through discussion that includes an explanation and demonstration, through the use of data, of benefits accruing from in-prison OST, including easier incarceration with less desire to inject an illicit drug [17] and the potential for less violence [16], less risk for prolonging incarceration or of irritating prison staff [2], less risk for acquiring an infectious disease [5] and less risk for self-harm. Other benefits that may be demonstrated are realised after release from prison, including less desire to commit crime and, consequently, lower risk for re-incarceration and lower risks for violence, potentially lethal overdose [18] and infectious disease [44].

#### ***Overcoming barriers from the prison staff and other stakeholders***

Stakeholders who lack understanding or misunderstand the value of maintenance treatment in prisons—and who may block the implementation of a treatment programme—include politicians, ministerial representatives and prison staff and professionals. A necessary step in convincing stakeholders to support the development of an OST programme is to educate them on the nature of the opioid drug problem among prisoners and on evidence-based benefits of successful OST, including health economics benefits.

Stakeholders need instruction that opioid dependence is a chronically relapsing disease [24] and that coercive abstinence in prison may be followed by relapse immediately after release, often resulting in overdose, drug emergencies and death [19]. This education may include evidence of beneficial results of OST, including reduced rates of drug abuse, both in prison and after release from prison [23,25,35,36,39], less risk-taking behaviour [11,38], reduced rate of infectious disease acquisition [39,42], reduced risk for death [42], decrease in serious violent drug charges [21], reduced criminal activity after release [44] and reduced re-incarceration rate [21,42,45,46]. Outcomes and health economic data demonstrating results of studies showing the cost-effectiveness of drug maintenance therapy in prisons [21,47] should be included. Techniques and resources to gain support for instituting an OST programme and to disseminate information in support of such a pro-

gramme include initiating and maintaining contact with decision-making politicians, the media, the professional public and non-governmental organisations such as human rights agencies, the United Nations Office on Drugs and Crime and the World Health Organization Regional Office for Europe Health in Prison Project. Other techniques for obtaining and building support for a programme include publishing and making available information on best OST practices; promoting the exchange of knowledge and experience among scientists, politicians and practitioners through international and national conferences of experts from various fields; and organising local and regional discussions among interested physicians. Finally, identifying local “champions” who can knowledgeably explain models of best practice to their peers and to provide opportunities for personnel who are interested in starting an OST programme to visit prisons where successful harm reduction programmes are in operation can be invaluable in the process.

Stakeholders should be informed that an OST programme must provide for the supply of OST medications. Lack of access to these medications is often a barrier to the successful implementation of an OST programme. Prisons may have a limited list of medications available for dispensing, and OST maintenance medications may not be among those available. In some cases, there may not be medication available to continue maintenance therapy that was started before imprisonment. Prisoners usually do not have health insurance while in prison and thus cannot afford medication they could afford outside prison; they are dependent for their medications on a prison’s health care system.

Prison staffs often express a concern that an OST programme introduces the potential risk for internal diversion of maintenance drugs [17]. In some studies, such diversion was suspected [40], whereas in others it was found not to be a problem [36]. When diversion was suspected, it was because of actions such as movement of a prisoner’s hand to the face when sublingual buprenorphine was administered [40]. Because it takes 5 to 10 minutes for a buprenorphine tablet applied sublingually to be absorbed completely, there is time for it to be removed from the mouth after insertion for subsequent potential black-market sale. Prison personnel are often unwilling to spend the time necessary to observe each administered dose of buprenorphine in order to prevent its extraction from the mouth and diversion. Thus, instead of buprenorphine tablets, prisons are increasingly administering tablets combining buprenorphine and naloxone to reduce potential diversion and misuse: applied sublingually, the naloxone is poorly absorbed and has limited pharmacological effect, whereas the efficacy of the buprenorphine is not affected by the presence of naloxone. If a buprenorphine/naloxone tablet is crushed and used intravenously, the naloxone is bioavailable; it will counteract the potential euphoric effect of the buprenorphine and can precipitate severe opioid withdrawal, a strong deterrent to intravenous misuse of diverted buprenorphine/naloxone [28].

Finally, lack of adequate funding to cover start-up costs of a prison OST programme constitutes a barrier to implementing a programme. To remove this barrier, the following items must be covered in a programme’s start-up budget: general administration and administration of the OST programme; medical and nursing staffs to execute maintenance therapy assessments, administration and delivery; pharmacy and courier services for stocking, preparation and delivery of medications; disposable materials used in medicating prisoners; maintenance medication; and correction officers to supervise medication administration to prisoners [47].

## **Conclusion**

Imprisoned IDUs have the basic right to receive treatment for their drug addiction comparable to treatment available to IDUs in the community. This treatment should include OST, a treatment modality with demonstrated broad benefits to prisoners, both while they are incarcerated and after their release from prison, as well as benefits to the institution and to the community. Examples of successfully implemented OST programmes exist, and these point to effective strategies and tactics for establishing OST programmes elsewhere.

The barriers of access to proven, and accepted methods and goals of treatment (compared with OST in the

community) need to be turned down in the intramural addiction medicine, to avoid discontinuities in the time spent in prison and afterwards.

## References

1. **European Commission Health & Consumer Protection Directorate-General. Models of good practice in drug treatment in Europe (MoreTreat): final report.** [[http://ec.europa.eu/eahc/documents/projects/highlights/2007\\_5986\\_EN\\_82.pdf](http://ec.europa.eu/eahc/documents/projects/highlights/2007_5986_EN_82.pdf)]
2. Shewan D, Stöver H, Dolan K: **Injecting in prisons.** In *Injecting Illicit Drugs*. Edited by Pates R, McBride A, Arnold K. Oxford, UK: Blackwell Publishing Ltd; 2005: 69-81.
3. Fazel S, Bains P, Doll H: **Substance abuse and dependence in prisoners: a systematic review.** *Addiction* 2006, **101**:181-191.
4. Rich JD, Boutwell AE, Shield DC, Key RG, McKenzie M, Clarke JG, Friedmann PD: **Attitudes and practices regarding the use of methadone in US state and federal prisons.** *J Urban Health* 2005,**82**:411-419.
5. **Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners. Bonn, Germany: European Commission 2008.** [[http://ec.europa.eu/health/ph\\_determinants/life\\_style/drug/documents/drug\\_frep1.pdf](http://ec.europa.eu/health/ph_determinants/life_style/drug/documents/drug_frep1.pdf)]
6. Jürgens R, Ball A, Verster A: **Interventions to reduce HIV transmission related to injecting drug use in prison.** *Lancet Infect Dis* 2009,**9**:57-66.
7. **Progress on implementing the Dublin Declaration on Partnership to fight HIV/AIDS in Europe and Central Asia.** [[http://www.euro.who.int/eprise/main/WHO/Progs/SHA/treatment/20051018\\_1](http://www.euro.who.int/eprise/main/WHO/Progs/SHA/treatment/20051018_1)]
8. Wood E, Lim R, Kerr T: **Initiation of opiate addiction in a Canadian prison: a case report.** *Harm Reduction J* 2006,**3**:11.
9. Allwright S, Bradley F, Long J, Barry J, Thornton L, Parry JV: **Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey.** *BMJ* 2000,**321**:78-82.
10. Shewan D, Macpherson A, Reid MM, Davies JB: **Patterns of injecting and sharing in a Scottish prison.** *Drug Alcohol Depend* 1995,**39**:237-243.
11. Darke S, Kaye S, Finlay-Jones R: **Drug use and injection risk-taking among prison methadone maintenance patients.** *Addiction* 1998,**93**:1169-1175.
12. Lines R, Jürgens R, Stöver H, Kaliakbarova G, Laticevschi D, Nelles J, MacDonald M, Curtis M: **Dublin Declaration in HIV/AIDS in prisons in Europe and Central Asia: prison health is public health.** *Can HIV AIDS Policy Law Rev* 2004,**9**:41-45.

13. Haber PS, Parsons SJ, Harper SE, White PA, Rawlinson WD, Lloyd AR: **Transmission of hepatitis C within Australian prisons.** *Med J Aust* 1999,**171**:31-33.
14. O'Sullivan BG, Levy MH, Dolan KA, Post JJ, Barton SG, Dwyer DE, Kaldor JM, Grulich AE: **Hepatitis C transmission and HIV post-exposure prophylaxis after needle- and syringe-sharing in Australian prisons.** *Med J Aust* 2003,**178**:546-549.
15. Keppeler K, Stöver H: **[Transmission of infectious diseases during imprisonment--results of a study and introduction of a model project for infection prevention in Lower Saxony].** *Gesundheitswesen* 1999,**61**:207-213.
16. Friedmann PD, Melnick G, Jiang L, Hamilton Z: **Violent and disruptive behavior among drug-involved prisoners: relationship with psychiatric symptoms.** *Behav Sci Law* 2008,**26**:389-401.
17. Stallwitz A, Stöver H: **The impact of substitution treatment in prisons--a literature review.** *Int J Drug Policy* 2007,**18**:464-474.
18. **Drug-related mortality among newly released offenders.** London, UK: Home Office Findings 187; 2003. [<http://www.homeoffice.gov.uk/rds/pdfs2/r187.pdf>]
19. Farrell M, Marsden J: **Acute risk of drug-related death among newly released prisoners in England and Wales.** *Addiction* 2008,**103**:251-255.
20. **Drug-related mortality among newly released offenders 1998 to 2000.** London, UK: Home Office Findings; 2005. [<http://www.homeoffice.gov.uk/rds/pdfs05/rdsolr4005.pdf>]
21. **Institutional methadone maintenance treatment: impact on release outcome and institutional behaviour.** Ottawa, ON, Canada: Addictions Research Centre Research Branch: Correctional Service Canada. [[http://198.103.98.138/text/rsrch/reports/r119/r119\\_e.pdf](http://198.103.98.138/text/rsrch/reports/r119/r119_e.pdf)]
22. Larney S, Dolan K: **A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care?** *Eur Addict Res* 2009,**15**:107-112.
23. Michel L, Maguet O: **[Guidelines for substitution treatments in prison populations].** *Encephale* 2005,**31**:92-97.
24. Stöver H, Casselman J, Hennebel L: **Substitution treatment in European prisons: a study of policies and practices in 18 European countries.** *Int J Prisoner Health* 2006,**2**:3-12.
25. Michels II, Stöver H, Gerlach R: **Substitution treatment for opioid addicts in Germany.** *Harm Reduction J* 2007,**4**:5.
26. Michel L, Carrieri MP, Wodak A: **Harm reduction and equity of access to care for French prisoners: a review.** *Harm Reduction J* 2008,**5**:17.
27. **2008 Annual report: the state of the drugs problem in Europe.** Lisbon, Portugal: EMCDDA; 2008. [<http://www.emcdda.europa.eu/publications/annual-report/2008>]

28. **Opioid substitution treatment in custodial settings: a practical guide.** Oldenburg, Germany: BIS-Verlag; 2008. [<http://www.unodc.org/documents/baltics/OST%20in%20Custodial%20Settings.pdf>]
29. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE: **Buprenorphine use: the international experience.** *Clin Infect Dis* 2006,**43**:S197-S215.
30. Springer SA, Bruce RD: **A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners.** *J Opioid Manage* 2008,**4**:81-86.
31. Gjersing LR, Butler T, Caplehorn JRM, Belcher JM, Matthews R: **Attitudes and beliefs towards methadone maintenance treatment among Australian prison health staff.** *Drug Alcohol Rev* 2007,**26**:501-508.
32. Sheard L, Wright NMJ, El-Sayeh HG, Adams CE, Li R, Tompkins CNE: **The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification.** *Subst Abuse Treatment Prev Policy* 2009,**4**:1.
33. Stöver H: **Drug substitution treatment and needle exchange programs in German and European prisons.** *J Drug Issues* 2002,**32**:573-595.
34. **Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention.** [[http://www.unodc.org/docs/treatment/Brochure\\_E.pdf](http://www.unodc.org/docs/treatment/Brochure_E.pdf)]
35. **Views of recidivists released after participating in the NSW prison methadone program and the problems they faced in the community: evaluation of the NSW Department of Corrective Services Prison Methadone Program: Study 8. New South Wales, Australia.** [[http://www.dcs.nsw.gov.au/information/research\\_and\\_statistics/research\\_publication/rp021.pdf](http://www.dcs.nsw.gov.au/information/research_and_statistics/research_publication/rp021.pdf)]
36. Heimer R, Catania H, Newman RG, Zambrano J, Brunet A, Ortiz AM: **Methadone maintenance in prison: evaluation of a pilot program in Puerto Rico.** *Drug Alcohol Depend* 2006,**83**:122-129.
37. Dolan K, Hall W, Wodak A: **Methadone maintenance reduces injecting in prison.** *BMJ* 1996,**312**:1162.
38. Dolan KA, Wodak AD, Hall WD: **Methadone maintenance treatment reduces heroin injection in New South Wales prisons.** *Drug Alcohol Rev* 1998,**17**:153-158.
39. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD: **A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system.** *Drug Alcohol Depend* 2003,**72**:59-65.
40. Magura S, Lee JD, Hershberger J, Joseph H, Marsch L, Shropshire C, Rosenblum A: **Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial.** *Drug Alcohol Depend* 2009,**99**:222-230.
41. Gordon MS, Kinlock TW, Schwartz R, Albizu-Garcia C, Carabello-Correa G: **Buprenorphine for Puerto Rican prison inmates nearing release [abstract].** Presented at *Annual Meeting of the American Society of Criminology; 14-17 November 2007; Atlanta, GA.*

42. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD: **Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection.** *Addiction* 2005,**100**:820-828.
43. Mourino AM: **Behandlung mit Ersatzopiaten in einer katalanischen Strafvollzugsanstalt [poster].** Presented at *World Health Organization Meeting; March 1994; Athens, Greece.*
44. Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O'Grady KE: **A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease.** *J Subst Abuse Treat* 2009,**37**:277-285.
45. Levasseur L, Marzo JN, Ross N, Blatier C: **[Frequency of re-incarcerations in the same detention center: role of substitution therapy. A preliminary retrospective analysis].** *Ann Med Interne* 2002,**153**:1S14-1S19.
46. Sibbald B: **Methadone maintenance expands inside federal prisons.** *CMAJ* 2002,**167**:1154.
47. Warren E, Viney R, Shearer J, Shanahan M, Wodak A, Dolan K: **Value for money in drug treatment: economic evaluation of prison methadone.** *Drug Alcohol Depend* 2006,**84**:160-166.
48. Barnett PG, Hui SS: **The cost-effectiveness of methadone maintenance.** *Mt Sinai J Med* 2000,**67**:365-374.
49. Rincon-Moreno S: **Ten years of methadone maintenance programs in Spanish prisons (1996-2005) [abstract].** Presented at *4th International Conference on Alcohol and Harm Reduction; 12 May 2008; Barcelona, Spain.*
50. Keppler K, Stöver H, Schulte B, Reimer J (2010): **Prison Health is Public Health! Angleichungs- und Umsetzungsprobleme in der gesundheitlichen Versorgung Gefangener im deutschen Justizvollzug.** *Bundesgesundheitsblatt – Gesundheitsforschung - Gesundheitsschutz* 2010, **53**, H. 2/3: 233–244
51. Stöver H, Marteau D (2010): **Scaling-Up of Opioid Substitution Treatment in Adult Prison Settings – Scientific Evidence and Practical Experiences.** *International Journal of Prisoner Health* (6,3, in press)
52. Marteau D, Stöver H (2010): **The introduction of the prisons “Integrated Drug Treatment System (IDTS)” in England.** *International Journal of Prisoner Health* (6,3, in press)
53. Marteau D, Stöver H (2010): **„Scaling-Up Substitution Treatment in Custodial Settings - Evidence and Experiences”.** [Poster, presented at 5th European Conference on Clinical and Social Research on AIDS and Drugs / Vilnius 28 - 30 April 2009]
54. Larney S.: **Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review.** *Addiction* **105**, 216-223

55. Stöver H (2010): **Weiterentwicklung der Substitutionsbehandlung Opioidabhängiger:** Die IMPROVE-Studie. In: Blickpunkt Medizin, Suchttherapie. *Suchttherapie*, H. 2/2010, S. 1-4; siehe auch *Dt. Ärzteblatt: Angebote für Drogenabhängige regional unterschiedlich*. 27.1.2010  
<http://www.aerzteblatt.de/v4/news/news.asp?id=39844&src=suche&p=st%F6ver>

**Korrespondenzadresse /  
Address for correspondence:**

Prof. Dr. Heino Stöver  
Institute of Addiction Research  
University of Applied Sciences  
Nibelungenplatz 1  
D-60318 Frankfurt am Main  
Email: [hstoever@fb4.fh-frankfurt.de](mailto:hstoever@fb4.fh-frankfurt.de)

Veröffentlicht / Published:  
12. August 2010 / August 12, 2010

Eingereicht / Received:  
4. August 2010/ August 4, 2010

Angenommen / Accepted:  
11. August 2010/ August 11, 2010